Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3490479 | 0.83 | KDM4E (0.45) | SMN1; SMN2RAB9ANPC1AURKAGSK3A | |
| SCHEMBL3491183 | 0.78 | GSK3B (0.52) | SMN1; SMN2RAB9ANPC1TSHRAURKA | |
| SCHEMBL3492922 | 0.78 | GSK3B (0.59) | MAPK1KMT2AL3MBTL1SMN1; SMN2ALOX15 | |
| SCHEMBL1268416 | 0.75 | SMN1; SMN2 (0.61) | KMT2AL3MBTL1SMN1; SMN2ALOX15RAB9A | |
| SCHEMBL6622178 | 0.75 | MAPK14 (0.75) | KMT2ARAB9ANPC1MEN1 | |
| SCHEMBL3492974 | 0.75 | MAPK10 (0.46) | KMT2ARAB9ANPC1MEN1AURKA | |
| SCHEMBL1269221 | 0.73 | SMN1; SMN2 (0.63) | KMT2AL3MBTL1SMN1; SMN2ALOX15RAB9A | |
| SCHEMBL1475683 | 0.71 | RAB9A (0.70) | MAPK1KMT2AL3MBTL1SMN1; SMN2ALOX15 | |
| SCHEMBL30633337 | 0.71 | MAPK1 (0.60) | MAPK1SMN1; SMN2ALOX15RAB9ANPC1 | |
| SCHEMBL26686503 | 0.71 | MAPK1 (0.60) | MAPK1SMN1; SMN2ALOX15RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492378-B2 | GSK-3β inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | MAPK1 251/4885KMT2A 1247/4885L3MBTL1 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.